APA (7th ed.) Citation

Fenaux, P., Santini, V., Komrokji, R. S., Zeidan, A., Garcia-Manero, G., Buckstein, R., . . . Platzbecker, U. (2022). P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL. Wiley.

Chicago Style (17th ed.) Citation

Fenaux, P., et al. P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL. Wiley, 2022.

MLA (9th ed.) Citation

Fenaux, P., et al. P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL. Wiley, 2022.

Warning: These citations may not always be 100% accurate.